About Pepscan
Pepscan is a Healthcare company based in Lelystad (Netherlands) founded in 2000, and was acquired by Biosynth in June 2022. Pepscan employs protein mimicry techniques for the RD of therapeutic drugs and a range of specialty peptide products and services. Pepscan has raised $8.86 million across 2 funding rounds from investors including European Union, Biosynth and Oost NL. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics and 5 more; 9 of its 10 listed competitors have raised funding.
Company details
Founded in 2000 and based in Lelystad, Netherlands, Pepscan operates in the biotechnology sector, focusing on peptide-based solutions. Custom services such as peptide synthesis, epitope mapping, peptide arrays, and immunology and antibody assays are offered through Pepscan Presto BV. Collaborative RD projects for new peptide therapeutics are conducted via Pepscan Therapeutics BV, under the oversight of Pepscan Holding NV.
- Headquarters Lelystad, Netherlands
- Stage Acquired
- SectorsHealthcare
- Website pepscan.com
- Social LinkedIn
- Acquired by Biosynth (Jun 2022)
- Total Equity Funding$8.86M (USD)
in 2 rounds
- Latest Funding Round$294.3K (USD), Grant
Jan 2023
- InvestorsEuropean Union
& 5 more
- Acquired byBiosynth
(Jun 2022)
Funding Insights of Pepscan
Pepscan has successfully raised a total of $8.86M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $294.3 thousand completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.86M
- Total Rounds 2
- Last Round Grant — $294,303
- First Round $8.86M
(Sep 2006)
- Investors Count 5
All 2 funding rounds of Pepscan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2023 | $294,303 | Grant | – | – | |
| Sep 2006 | $8.86M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in Pepscan
Pepscan has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Biosynth and Oost NL.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sector-agnostic VC firm investing in geographies such as the Netherlands | 2003 | oostnl.nl | Apeldoorn, Netherlands | |
- | – | lupusventures.nl | - | |
- | – | technofundflevolandbv.tcc.mode | - | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
- | – | bioxbiosciencesbv.tcc.mode | - | |
Biosynth is engaged in supplying critical raw materials and services for life sciences and diagnostics. | 1966 | biosynth.com | Thal, Switzerland |
Investor details for Pepscan
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Pepscan
4 dated milestones of Pepscan across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Pepscan is founded.
- Funding First funding round of $8.9M.
- Exit Acquired by Biosynth.
- Funding Latest funding round, Grant, of $294K.
Competitors of Pepscan
Pepscan has 10 listed competitors in our database, 9 of them funded. They include GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| lifeminetx.com | 2016 | Cambridge, United States | $300.07M | 85 | Developer of novel drugs from fungi via genome mining and recombinant overexpression |
Detailed competitors of Pepscan
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Pepscan
Websites that share an audience with Pepscan (pepscan.com).
Websites whose visitors overlap most with Pepscan. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| funakoshi.co.jp | 100% | – | #235,866 | View details | |
proteogenix-antibody.com | proteogenix-antibody.com | 100% | – | – | – |
| lifetein.com | 100% | – | #1,173,853 | View details | |
peptideresource.com | peptideresource.com | 99% | – | – | – |
peptide2.com | peptide2.com | 99% | – | #2,007,598 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Pepscan
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Pepscan (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pepscan
Complete news archive for Pepscan
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pepscan
Pepscan was founded in 2000 and raised its 1st funding round 6 years after it was founded.
Pepscan is headquartered in Lelystad, Netherlands. It is registered at Lelystad, Flevoland, Netherlands.
Pepscan is a funded company, having raised a total of $8.86M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.86M, raised on Sep 2006.
Founded in 2000 and based in Lelystad, Netherlands, Pepscan operates in the biotechnology sector, focusing on peptide-based solutions. Custom services such as peptide synthesis, epitope mapping, peptide arrays, and immunology and antibody assays are offered through Pepscan Presto BV. Collaborative RD projects for new peptide therapeutics are conducted via Pepscan Therapeutics BV, under the oversight of Pepscan Holding NV.
Pepscan's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Pepscan has 6 investors. Key investors include European Union, Biosynth, Oost NL, Lupus Ventures, and BioX Biosciences BV.
Yes. Pepscan was acquired by Biosynth in June 2022.